Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Assets data on file, last reported at $61.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 2.2% year-over-year to $61.0 million in Q1 2026; TTM through Mar 2026 was $61.0 million, a 2.2% decrease from a year earlier, with the FY2025 full-year figure at $60.0 million, down 4.76% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $61.0 million, up from $60.0 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for RARE reached as high as $63.0 million in Q4 2024 and fell as low as $18.3 million in Q3 2022.
• Historically, Other Non-Current Assets has averaged $45.6 million across 5 years, with a median of $53.9 million in 2024.
• Across the five-year window, Other Non-Current Assets surged 169.42% in 2024 and slipped 4.76% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $48.3 million in 2022, then gained by 19.34% to $57.7 million in 2023, then grew by 9.21% to $63.0 million in 2024, then declined by 4.76% to $60.0 million in 2025, then grew by 1.67% to $61.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $61.0 million in Q1 2026, $60.0 million in Q4 2025, and $57.9 million in Q3 2025.